You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 1, 2011

Ensuring Smooth Registration of Pharmaceutical Products

Subscribe to Updates
PReMA Life

The registration of a pharmaceutical product with the Food and Drug Administration (FDA) can be extremely time consuming, even for straightforward cases. In order to avoid any delays, it is important that the product dossier be meticulously prepared prior to submitting all relevant documents to the FDA, especially the quality part of the documentation.

We discussed the issue with the Department of Medical Science (DMSc) quality part examiners to clarify the process, provide key pointers to avoid common mistakes, and obtain their views and opinions on some of the most common difficulties typically encountered when reviewing a dossier.

Regulatory Changes

Due to changes in requirements from ASEAN Harmonization of Standards and Technical Requirements for Pharmaceutical Products, applicants should carefully follow the developments of the regulations for product registration to ensure that there are no missing documents and that they have not overlooked any newly introduced requirements.

Method Verification and Method Validation

New applications will likely have to be filed for all non‐ASEAN compliant pharmaceutical products, or amendments will have to be made to the quality part of such products. This includes the Method Verification and Analytical Method Validation aspects.

The Method Verification is the confirmation procedure by performing the analytical method in complying with the compendia method for the users of such methods. The manufacturers who use the United States Pharmacopoeia analytical method have to demonstrate their competence in successfully operating the method by providing the documents to verify the suitability of such methods.

The Analytical Method Validation is a confirmatory process of performing several tests which are designed to verify that an analytical test system is suitable for its intended purpose, and is capable of providing useful and valid analytical data. Thus, Analytical Method Validation is required for a newly developed method, non compendia, such as an in‐house method (i.e., a method that was developed by the manufacturer itself), and modified compendia procedures etc.

Applicants should also ensure that references from pharmacopoeia are not obsolete when submitting documents for the analytical part of the assay.

Zone IVb Stability Data

All previously registered pharmaceutical products have until 2012 to amend the stability data provided in their respective dossiers. Zone IVb stability data of 30 C +-2, 75 +-5% RH is now required. This includes long term and real time Zone IVb Stability data, which is a new requirement

Carefully prepared data that meets the FDA guidelines will hopefully avoid any unnecessary delays and ensure the earliest and smoothest product launch.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

October 14, 2021
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2021. This guide outlines all of the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Guides to Doing Business series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource when planning an international business strategy or researching a new market.
Read More
October 11, 2021
A registration process for plant variety protection (PVP) has been in effect in Myanmar since enactment of the New Plant Variety Protection Law 2016, which was later replaced by the New Plant Variety Protection Law 2019 (“PVP Law 2019”). In accordance with its implementation of this law, the government is encouraging private companies, associations, organizations, and individual plant breeders to apply for the protection of new plant varieties in order to increase crop production in the country. Despite the challenges of the COVID-19 pandemic in Myanmar, Tilleke & Gibbins successfully secured a plant breeder’s rights certificate for a client in June 2020, making the client the first certificate holder in Myanmar. This article summarizes the PVP application and registration process, and offers some practical insights into the authorities’ activities and approach. PVP Registration The Central Committee for National New Plant Variety Protection (PVP Committee) oversees PVP registration, which is administered by the PVP Section of the Department of Agricultural Research (DAR) in the Ministry of Agriculture, Livestock, and Irrigation. To apply for plant breeder’s rights in Myanmar, an application and a technical questionnaire on the new plant variety should be filed with the PVP Section, which reviews the technical questionnaire and determines whether the plant qualifies as a new variety. Four groups are eligible to apply for PVP registration in order to secure plant breeder’s rights under the current PVP legislation: Myanmar nationals; Foreign nationals and organizations whose permanent residence is in Myanmar; Persons or entities resident in a country that has a PVP agreement with Myanmar; and International organizations. An application can be examined in one of four ways (determined by the PVP Committee): Official field trial involving planting the new variety in Myanmar; On-site field inspection of the breeder’s field by the PVP Section; Examination of test
Read More
August 27, 2021
The process of registering pesticide products in Myanmar has been slowed significantly by regulatory challenges since the enactment of the Pesticide Law in 2016. In some cases, the whole process can take almost three years. Nonetheless, this stringent and time-consuming process has been functioning smoothly, and Tilleke & Gibbins has successfully received approvals from the Pesticide Registration Board (PRB) despite the ongoing COVID-19 pandemic and state of emergency in the country. Overview Since its enactment, the Pesticide Law of 2016 has governed the regulation of local and imported pesticides under the oversight of the Plant Protection Division (PPD) and the joint secretary of the PRB. All foreign and domestic companies (including subsidiaries and joint ventures) looking to have their agricultural or household pest control products imported into Myanmar must first provide the products’ complete formulas and lists of active ingredients to the PPD, and apply for a pesticide registration certificate. Applications should be supported by a letter of consent from the manufacturer and various other technical documents and requirements. Experts at the PRB will review the technical dossier and inform the applicant if any re-submissions are required. Key Considerations One common cause of delay in the registration process is the requirement to submit both English and Myanmar translations of proposed labels to the PRB. Because the PRB takes a restrictive view of these labels and their translations, having the labels initially reviewed by a local regulatory expert familiar with the requirements will streamline the process by flagging potential issues for correction before submission to the PRB. After document submission is complete, the next stage of the process is further lab testing according to requirements set out by the Myanmar Pesticide Law. Applicants will need to supply the formulated product in an amount sufficient for carrying out supervised trials and
Read More
August 26, 2021
The Ministry of Health of Vietnam recently issued Circular No. 10/2021/TT-BYT dated June 30, 2021, stipulating the list of substances prohibited from use in the production and trading of health supplements (“Circular 10”). Circular 10 will come into effect on September 1, 2021. Accordingly, substances found on the following lists will be prohibited from use in health supplements: The list of drugs and drug materials prohibited from importation and production found in Annex V of Decree No. 54/2017/ND-CP of the Government dated May 8, 2017, guiding the implementation of Law on Pharmacy (Decree 54). Lists promulgated with Decree No. 73/2018/ND-CP of the Government dated May 15, 2018, stipulating the list of narcotic substances and precursors, including: List I: Narcotic substances banned from use in healthcare and daily life, the use of which for analysis, testing, scientific research, and criminal investigation is subject to permission by competent authorities. List II: Narcotic substances restricted from analysis, testing, scientific research, criminal investigation, or healthcare as regulated by competent authorities. List III: Narcotic substances permitted in analysis, testing, scientific research, criminal investigation, healthcare, and veterinary medicine as regulated by competent authorities. List IVA: Essential precursors involved in forming the structure of narcotic substances. The list of narcotic active ingredients found in Annex I of Circular No. 20/2017/TT-BYT of the Ministry of Health, detailing articles of the Law on Pharmacy and Decree 54 related to drugs and drug materials under special control. The list of toxic drugs and toxic drug materials under Circular No. 06/2017/TT-BYT of the Ministry of Health dated May 3, 2017. Lists under Circular No. 42/2017/TT-BYT of the Ministry of Health dated November 13, 2017, stipulating the lists of toxic herbal materials, including: Annex I: List of toxic herbal materials of plant origin. Annex II: List of toxic herbal materials of
Read More